Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EFFECTIVENESS OF PNEUMOCOCCAL VACCINATION (PCV20) TO PREVENT ALL-CAUSE PNEUMONIA AND LOWER RESPIRATORY TRACT INFECTIONS AMONG ADULTS ≥19 YEARS OF AGE WITH AN INCREASED RISK OF PNEUMOCOCCAL DISEASE AT KAISER PERMANENTE SOUTHERN CALIFORNIA

NCT07251465 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT07251465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07251465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EFFECTIVENESS OF PNEUMOCOCCAL VACCINATION (PCV20) TO PREVENT ALL-CAUSE PNEUMONIA AND LOWER RESPIRATORY TRACT INFECTIONS AMONG ADULTS ≥19 YEARS OF AGE WITH AN INCREASED RISK OF PNEUMOCOCCAL DISEASE AT KAISER PERMANENTE SOUTHERN CALIFORNIA
Lead sponsor
Pfizer
Phase
Observational
Overall status
Active, not recruiting
Start date
January 21, 2026
Completion date
September 30, 2026
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

community-acquired pneumonia (cap)